Product Ref: VICAN20 Category: C
Royal Mail 2nd Class / Parcel Force 48
UK to UK :Normally arrives in 2-4 business days.
UK to Ireland :Normally arrives in 4-6 business days
UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going
Please note standered delivery is none trackable , none insured , no responsabily for lose or Damage
----------------------------------------------------------------------------------------------------------------
Royal Mail First Class / Parcel Force 24
UK to UK :Normally arrives in 1-2 business days.
UK to Ireland 3-4 business days
UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going
Please note :Trackable , Royal Mail insured up to £50.
--------------------------------------------------------------------------------------------------------
Parcel Force Express AM Guaranteed before Midday.
UK to UK only . UP to 5KG Max Weight
Arrives next day before 12 noon, requires a signature.
Parcel Forcel Terms & Conditions apply
Important: Parcel Force advise that there are some postcodes where an extended delivery time exists, and may affect the date of delivery or the service is not available.
| Category | POM-V |
| Temperature | Refrigerated |
| MA/VM/EU No: | 01708/4539 |
| Species |
|
| VMD Link | Product Information Database (defra.gov.uk) |
| NOAH Link | https://www.noahcompendium.co.uk/?id=-460042 |
| Dosage | Dosage and administration The contents of one vial of reconstituted vaccine should be injected subcutaneously. Reconstitute immediately prior to use by the addition of the contents of one vial (1.0 ml) of Canigen Lepto 2 (canine leptospirosis vaccine), Canigen Rabies, or Canigen Lepto 4 . Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation. Primary course vaccination A single injection should establish active immunity to disease caused by canine parvovirus infection in dogs of 10 weeks of age or older. Where earlier protection is required a first dose may be given to puppies from 4 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination a final dose at 10 weeks of age or older is generally recommended. Booster vaccination It is recommended that dogs be revaccinated every 3 years. Further information Experience has shown that the maternal antibody status of pups within a litter varies greatly and reliance should not be placed on serological examination of the bitch alone. A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. The immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress. Can be used in pregnant bitches which have previously been vaccinated with the CPV (strain 154) antigens included in the Canigen vaccine series. Contra-indications, warnings, etc Do not use in unhealthy dogs. The vaccine may not be effective in dogs incubating the disease at the time of vaccination. Some animals may be immunologically incompetent and fail to respond to vaccination. Animals that have received the corresponding anti-serum or immunosuppressive drugs should not be vaccinated until an interval of at least 4 weeks has elapsed. After administration with one of the leptospirosis vaccines, a mild and transient increase in body temperature (≤ 1°C) may occur for a few days after vaccination, with some pups showing less activity and/or a reduced appetite. A small transient swelling (≤ 4 cm), which can occasionally be firm and painful on palpation, may be observed at the site of injection. Any such swelling will either have disappeared or be clearly diminished by 14 days post-vaccination. After mixed administration of an overdose of Canigen Parvo-C and an overdose of the leptospirosis vaccines of the Canigen series, transient local reactions such as diffuse to firm swellings from 1 to 5 cm in diameter may be observed, usually these will persist no longer than 5 weeks, however some may take a little longer to completely disappear. Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with the inactivated vaccine of the Canigen series against rabies. After administration with the rabies vaccine, where this product is authorised, transient local reactions such as diffuse to firm swellings from 1 to 4 cm in diameter may be observed for up to 3 weeks after vaccination. The swellings may be painful for up to 3 days post dosing. In the rare event of a hypersensitivity reaction occurring following vaccination, administer an antihistamine, corticosteroid or adrenaline, without delay and by the most immediate route. After administration of an overdose, a response similar to that following a single dose may be seen. In some dogs the swelling may be more painful or may be observed for a longer period. If you notice any serious effects not mentioned on this leaflet, please inform your veterinary surgeon. The vaccine strain may be shed at very low levels for up to 8 days after inoculation. However there is no evidence of any reversion to virulence of the vaccine strain and therefore no need to separate unvaccinated dogs from contact with recently vaccinated individuals. Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day with Canigen Lepto 4, Canigen Lepto 2 or Canigen Rabies. These can be used to reconstitute the freeze-dried Canigen Parvo-C. No information is available on the saefty and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. Do not mix with any other medicinal product except Canigen Lepto 2, Canigen Lepto 4 or Canigen Rabies. The efficacy of the CPV component of the vaccine may be reduced due to maternal antibody interference. However, the vaccine has been proven to be of benefit against virulent challenge in the presence of maternal antibody levels to CPV that are likely to be encountered under field conditions. |
| Withdrawals |
